The Biomarker Edge is Alamar Biosciences’ thought leadership series featuring conversations and content from leading scientists, clinicians, and translational researchers at the forefront of fluid biomarker discovery. Through expert interviews and in-depth blogs, the series explores how cutting-edge technologies like NULISA™ are transforming research and diagnostics across a wide range of diseases.
From neurodegenerative diseases like Alzheimer’s and Parkinson’s, to oncology, inflammation, and autoimmune disorders, The Biomarker Edge brings clarity to the challenges—and opportunities—of measuring ultra-low abundance proteins from plasma and other biofluids.
In-depth discussions with scientific and clinical experts driving innovation in fluid biomarker discovery.
In this third episode of The Biomarker Edge, Dr. Cheryl Wellington from the University of British Columbia, discusses her work advancing fluid biomarkers in Alzheimer’s disease, traumatic brain injury, and stroke. She shares insights on launching a new biomarker core facility, building collaborations with over 120 clinical partners, and expanding biomarker applications from pediatric to geriatric care. Dr. Wellington highlights how ultra-sensitive, multiplexed technologies like ARGO™ and NULISA™ are enabling low-volume specimen analysis, broad biomarker panels, and translational research that bridges clinical and pre-clinical models.
In this second episode of The Biomarker Edge, Dr. Ashton, A global leader in Alzheimer’s and neurodegeneration research, shares his latest work on blood-based biomarkers including p-tau217, NfL, GFAP, and other emerging candidates. He discusses the importance of brain-specific versus peripheral signals, the challenges of clinical translation, and how ultra-sensitive, multiplexed technologies like NULISA™ are accelerating progress toward earlier and more accurate diagnosis of Alzheimer’s and related dementias.
In this premiere episode of The Biomarker Edge, world-renowned neurologist and biomarker expert Dr. Henrik Zetterberg discusses the urgent need for ultra-sensitive, multiplexed fluid biomarker assays to advance neurodegenerative disease research. Dr. Zetterberg shares insights on the future of blood-based biomarker detection for Alzheimer’s disease, Parkinson’s disease, and other CNS disorders—and how new technologies like NULISA™ are redefining what’s possible in early detection and disease monitoring.
Unpacking key challenges in fluid biomarker discovery and how NULISA is solving them
Geoffrey Feld, Ph.D. Geocyte LLC & Alamar Biosciences collaborator Topic/Product: Disease Area: Sample Type: “This is personal to me. The early detection of cancer is
Stephen A. Williams, MD, PhD, Chief Scientific Officer, Alamar Biosciences Disease Area: Sample Type: Anyone would think a revolution is imminent: “Blood tests could reshape
Geoffrey Feld, Ph.D. Geocyte LLC & Alamar Biosciences collaborator Topic/Product: Alternative Sample types Disease Area: Sample Type: According to the National Center for Advancing Translational Sciences at
Geoffrey Feld, Ph.D. Geocyte LLC & Alamar Biosciences collaborator Topic/Product: Alternative Sample types Disease Area: Sample Type: Doctors and clinicians already rely on routine blood
Geoffrey Feld, Ph.D. Geocyte LLC & Alamar Biosciences collaborator Topic/Product: Sample types Disease Area: Sample Type: Like the heroic Argonauts of ancient Greek mythology, researchers
Geoffrey Feld, Ph.D. Geocyte LLC & Alamar Biosciences collaborator Topic/Product: Biomarker Analysis Disease Area: Sample Type: So far in this Biomarker Edge series, we’ve learned
Geoffrey Feld, Ph.D. Geocyte LLC & Alamar Biosciences collaborator Topic/Product: Alternative Sample types Disease Area: Sample Type: Traditional proteomics is a little like Count Dracula,
Geoffrey Feld, Ph.D. Geocyte LLC & Alamar Biosciences collaborator Topic/Product: Disease Area: Sample Type: By: Geoffrey Feld, Ph.D.Geocyte LLC & Alamar Biosciences collaborator A Numbers
CSO
Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.
CFO
Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.